Stabilized liquid protein formulations in pharmaceutical...

Details Stabilized liquid protein formulations in pharmaceutical... Stabilized liquid protein formulations in pharmaceutical...

2004-05-12

2009-06-02

Landsman, Robert (Department: 1647)

Special receptacle or package

For ampule, capsule, pellet, or granule

C424S085600, C526S255000

Reexamination Certificate

active

07540382

ABSTRACT:
A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON (polytetrafluoruethylene (PTFE)) and contains a HSA-free Interferon-β formulation having the following composition: 30 to 100 μg/ml of interferon-β, an isotonicity agent, 0.1 to 2 mg/ml of Poloxamer 188, at least 0.12 mg/ml of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.

REFERENCES:
patent: 5183746 (1993-02-01), Shaked et al.
patent: 5661125 (1997-08-01), Strickland
patent: 6171586 (2001-01-01), Lam et al.
patent: 2004/0043973 (2004-03-01), Ahlem et al.
patent: 0 641 567 (1995-03-01), None
patent: 0 736 303 (1996-10-01), None
patent: 97/17087 (1997-05-01), None
patent: 98/28007 (1998-07-01), None

Affiliated with

Also associated with

Rating

Stabilized liquid protein formulations in pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stabilized liquid protein formulations in pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized liquid protein formulations in pharmaceutical... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4093512